Catalog #CP118
RecombiMAb anti-mouse CD19
Clone
1D3-CP118
Reactivities
Mouse
Isotype
Mouse IgG2a
(switched from rat IgG2a)
(switched from rat IgG2a)
You may also be interested in:
Product Description
The 1D3-CP118 monoclonal antibody is a chimeric version of the original 1D3 antibody. The variable domain sequences are identical but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. CP118 antibody has an effector function competent Fc domain allowing for activation of Fcγ receptors (FcγRs) to trigger antibody‑dependent cellular cytotoxicity (ADCC), antibody‑dependent cellular phagocytosis (ADCP), complement‑dependent cytotoxicity (CDC) and opsonization to promote target cell depletion. The mouse IgG2a isotype demonstrates strong effector functions due to potent interaction with mFcγRIV, which is functionally similar to the FcγRIIIa receptor involved in human ADCC. Species-matched chimeric antibodies result in less immunogenicity and formation of anti-drug antibodies (ADAs) than xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies.
The 1D3-CP118 monoclonal antibody reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily. CD19 contains two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. It functions as a positive regulator of B-cell receptor signaling in conjunction with CD21 and CD81. CD19 is highly expressed on autoreactive B cells and in most lymphomas and leukemias including some early B-cell malignancies that do not express CD20. For these reasons CD19 is an attractive target for the immunotherapy of lymphoproliferative disorders and autoimmune disease.
The 1D3-CP118 monoclonal antibody reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily. CD19 contains two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. It functions as a positive regulator of B-cell receptor signaling in conjunction with CD21 and CD81. CD19 is highly expressed on autoreactive B cells and in most lymphomas and leukemias including some early B-cell malignancies that do not express CD20. For these reasons CD19 is an attractive target for the immunotherapy of lymphoproliferative disorders and autoimmune disease.
Specifications
| Isotype | Mouse IgG2a, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb mouse IgG2a isotype control, unknown specificity |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Immunogen | K562 cells expressing the extracellular domain of mouse CD19 |
| Reported Applications |
in vivo B cell depletion* in vivo CD19 neutralization* in vitro B cell negative selection* Flow cytometry* *Reported for the original rat IgG2a 1D3 antibody |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation* |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Purification | Protein G |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |
* Additional quality control measures for our InVivoPlus™ products include advanced binding validation, murine pathogen screening, protein aggregation screening, and ultra-low endotoxin levels. The superior quality of our InVivoPlus™ products will meet and exceed the strict demands and rigorous standards required for in vivo research. Learn more about the InVivoPlus™ difference here.